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Summary
Nuclear transfer to eggs or oocytes provides a poten-
tial route for cell-replacement therapies [1] because
oocytes directly reprogram transplanted mammalian
somatic-cell nuclei such that they have an embryo-
like pattern of gene expression. This includes a large
increase in the mRNA level of the stem-cell marker
gene oct4 [2]. We have developed a novel procedure
to identify new proteins that greatly increase the level
of oct4mRNA upon nuclear transfer. We have isolated
Xenopus oocyte proteins that bind to the regulatory
region of the mouse oct4 gene and identified these
by mass spectrometry. The proteins include the reti-
noic-acid-receptor g, a known repressor of oct4 tran-
scription, and Tpt1, a cancer-associated factor [3].
The depletion of transcripts of retinoic-acid receptor
g from oocytes increases oct4 and nanog transcrip-
tion as expected, and depletion of tpt1 transcripts in
oocytes reduces oct4 and nanog transcription in in-
jected HeLa nuclei. An elevation of tpt1 transcripts in
oocytes results in an earlier activation of oct4 tran-
scription. Therefore, we identify a novel role for tpt1
in activating pluripotency genes upon nuclear trans-
fer. Our results help to elucidate the mechanism by
which somatic-cell nuclei are reprogrammed to have
an embryo-like pattern of gene expression.
Results and Discussion
Apart from global chromatin decondensation [4–7], the
mechanisms and molecules involved in nuclear reprog-
ramming and in establishing pluripotency are not well
understood. oct4 is a gene that is normally expressed
only in pluripotent, embryo-like cells. It is not expressed
in somatic cells but is activated upon nuclear transfer
into oocytes and in embryonic stem (ES) cells [2, 8].
When development and differentiation proceed [9–12],
or when retinoic acid is present [13], oct4 transcription
is downregulated. Pluripotency proteins such as Oct4
and Nanog are transcription factors with essential roles
in permitting the proliferation of ES cells [14–16]. Even
though several proteins, such as GCNF [17], SF1 [18],
LRH1 [19], retinoic acid [18], and Sall4 [20], are already
*Correspondence: j.gurdon@gurdon.cam.ac.ukknown to regulate the oct4 promoter region in cultured
cells or in later development, it is still unknown what is
responsible for the activation of oct4 transcription,
which correlates with cloning efficiency [21, 22]. Xeno-
pus oocytes provide abundant material and contain pro-
teins that cause a large increase in the level of oct4
mRNA. The identification of such proteins is important
for a better understanding of generating pluripotency
and of the molecular events by which eggs or oocytes
reprogram somatic-cell nuclei.
To identify proteins that bind to the oct4 regulatory re-
gion, we have used radioactively labeled DNA oligos
corresponding to regions of the mouse oct4 promoter
(Figures 1A and 1B). These oligos were incubated in
oocyte extract and DNA-protein complexes analyzed
on gels. Many of the oocyte-derived proteins showed
sequence specificity for the oligos representing the
oct4 regulatory region, as shown by the addition of in-
creasing concentrations of unlabeled competitor DNA
(Figure 1C). Competition experiments with CpG methyl-
ated versus unmethylated oligos revealed that the pro-
teins prefer to bind to the unmethylated oligos (Fig-
ure 1D). To identify which proteins bind to the different
oligos, we recovered the proteins from gels and iden-
tified them by mass spectrometry. We have identified
proteins already known to have a function in nuclear
reprogramming and have thereby validated our proce-
dure. These proteins include nucleoplasmin [4, 7, 23]
and the histone-binding protein N1/N2 [24]. We identi-
fied FRGY2, which is involved in disassembling somatic
nucleoli in egg cytoplasm; this disassembly process ac-
companies nuclear reprogramming [25]. The retinoic-
acid receptor g was also identified. Retinoic acid
induces retinoic-acid receptors in cultured cells, and
an increase in both retinoic acid and its receptors
causes differentiation of pluripotent cells [13, 18]. A ret-
inoic-acid receptor has already been shown to bind to
the oct4 regulatory region [18]. Most intriguingly, we
have identified Tpt1 by using mass spectrometry with
oligo Sf1 (data not shown); Tpt1 has not so far been
implicated in regulating oct4 transcription.
Tpt1 stands for tumor translationally controlled pro-
tein 1. It is widely expressed and conserved throughout
vertebrates, and was first identified in a screen for genes
involved in tumor reversion. tpt1 is the gene that shows
the strongest differential expression between tumor and
tumor-reversed states in human leukemia and breast-
cancer cells [3]. tpt1 is strongly expressed in tumor cells
and is downregulated upon tumor reversal. Moreover,
when Tpt1 is inhibited in tumor cells, suppression of
the malignant phenotype is observed [3]. oct4 is ex-
pressed in tumor cells [26], and we recovered Tpt1
with our oligos. Hence, we decided to focus on Tpt1.
We tested whether Tpt1 binding to the Sf1 oligo could
be confirmed. We repeated the gel shift, but this time in
the presence of a Tpt1 antibody (Figure 2A). This resulted
in a supershift, indicating that Tpt1 in fact binds to the
Sf1 oligo and is not an artifact of the mass-spectrometry
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802Figure 1. Xenopus laevis Oocyte Proteins Bind Specifically to the
Mouse oct4 Promoter
(A) Diagram of the 2.3 kb regulatory region of the mouse oct4
gene (not to scale) [30]. The region contains a distal enhancer (DE),
a proximal enhancer (PE), and a promoter (P). Translation is initiated
at nucleotide +1. Four methyl-sensitive restriction sites are shown
(M). Double-stranded DNA oligo fragments were designed to repre-
sent fragments of the oct4 regulatory region, as aligned below the
diagram.
(B) oct4 promoter fragments (oligos) and their corresponding DNA
sequences.
(C) Specificity of protein binding to oligos was determined by com-
petition experiments, as shown here for the 2166 oligo. Oocyte
extract was added to P32-labeled oligos in the presence of an
increasing amount (12.5–50 mM) of competitor. The addition of
the same but unlabeled oligo resulted in a stronger decrease of
the gel-shift signal than the addition of an unspecific oligo of the
same length that is not represented in the oct4 upstream region.
This illustrates specificity for protein-oligo complex formation,
which was found in all oligos.
(D) Xenopus oocyte proteins are competed out less efficiently
with methylated oligos compared to the same oligos that are un-
methylated. Competition with increasing concentrations (12.5–
50 mM) of unlabeled oligos (unmethylated or methylated) revealed
a protein binding preference for unmethylated oligos (only shown
for the 2166 oligo). The following abbreviation is used: methylated
(Met).results. In addition, Tpt1 was also found to bind in vivo,
as determined by chromatin immunoprecipitation
(ChIP) analysis with Xenopus oocytes (Figure 2B).
To determine the developmental function of Tpt1, we
carried out a test that depends on the downregulation of
the tpt1 mRNA. We wanted to find out whether oct4 ac-
tivation is inhibited in reduced abundance of tpt1. Anti-
sense DNA oligos (ODN, oligo deoxynucleotides) that
successfully degrade endogenous tpt1 mRNA in living
oocytes were designed (Figures 2C and 2D). Antisense
oligos were also prepared for the identified retinoic-
acid receptor g (RAR), which serves as a control be-
cause of its known function in downregulating oct4 tran-
scription [18] (Figures 2C and 2E). After downregulation
of both tpt1 and RAR mRNAs, the levels of other oocyte
mRNAs were unchanged (Figure 2F). As a control, anti-
sense oligos against gfp did not cause downregulation
of any other genes tested (Figures 2C–2F). This sug-
gests that the antisense oligos against RAR and tpt1
act specifically. Moreover, antisense oligos againstXen-
opus tpt1 mRNA resulted in specific downregulation of
Xenopus Tpt1 protein but not of mouse Tpt1 protein,
which is not targeted by these antisense oligos
(Figure 2G).
To reinforce our evidence for the importance of tpt1
for oct4 activation, we have asked whether tpt1 is re-
quired for an increase in oct4 mRNA in nuclear-transfer
experiments. Forty hours after oocyte injection of anti-
sense oligos, approximately 100 HeLa nuclei were in-
jected into the germinal vesicles of oocytes, which
were cultured for up to 24 hr. We took different time
points and analyzed them by RT-PCR in order to ob-
serve the activation of oct4 (Figure 3A). Because our
method is very sensitive, we found that oct4 and nanog
were expressed in nonpluripotent cells, such as human
HeLa cells, but at a very low background level. However,
if a large number (several thousand) of nonpluripotent
HeLa cells was analyzed, the signal was strong and
was used as a positive control for the RT-PCR. The
time course revealed a gradual increase of oct4 mRNA
(Figure 3C). In control samples that were only injected
with HeLa nuclei and not antisense oligos, we observed
a 100-fold increase in oct4mRNA within several hours of
nuclear transfer (Yen-Hsi Kuo, personal communica-
tion). We find that oocytes depleted of RAR mRNA acti-
vate human oct4 transcription earlier and more strongly
than do oocytes with a normal endogenous level of RAR
(Figure 3C). This increased level of oct4 transcription
due to RAR mRNA downregulation agrees with previous
findings that RAR is an inhibitor of pluripotency and
induces differentiation [13, 18] and thus validates our
functional test. When antisense oligos against tpt1
were injected into oocytes, the opposite result was ob-
tained. We found that a reduction in the oocyte content
of tpt1 greatly reduced oct4 transcription (Figure 3D).
This suggests that tpt1 is involved in oct4 transcriptional
activation.
To test the specificity of our antisense oligo against
tpt1 mRNA, we have rescued Xenopus tpt1 depletion
by injecting mouse tpt1 mRNA into oocytes previously
injected with antisense oligos against tpt1 (Figure 3E).
Importantly, mouse tpt1 mRNA does not contain the se-
quence that is targeted by the Xenopus antisense oli-
gos. Hence, mouse tpt1 mRNA was not degraded and
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803Figure 2. Tpt1 Binds to oct4 DNA, and Its mRNA Can Be Downregulated in Xenopus laevis Oocytes
(A) The Tpt1 protein binds to the Sf1 oligo. An antibody bound to the Tpt1-Sf1 protein-oligo complex resulted in a supershift, confirming that Tpt1
binds the Sf1 oligo. As a control, the2166 oligo, which did not bind Tpt1 according to the mass spectrometry results, was used, and the antibody
did not shift the extract-oligo complex under these conditions.
(B) To confirm Tpt1 binding to the mouse oct4 promoter in vivo, we injected oocytes with HA-tagged tpt1-HA mRNA and an oct4 promoter-con-
taining plasmid, pOct4. A ChIP analysis was performed with an HA antibody and verified Tpt1 binding to the oct4 promoter. An H3 antibody was
used as a positive control, and the absence of antibodies served as a negative control. Error bars indicate the standard error of the mean (SEM).
The following abbreviation is used: antibody (Ab).
(C) Short antisense oligo deoxynucleotides (ODNs) were designed to target Xenopus laevis mRNA-encoding proteins identified by mass spec-
trometry (only Tpt1, RAR, and GFP control shown). Primers used for monitoring mRNA downregulation are indicated, together with the primers
used for detecting the Xenopus laevis housekeeping gene ornithine decarboxylase (ODC). The following abbreviations are used: forward (F), re-
verse (R).
(D) We injected 5 or 10 ng of different ODN oligos (Tpt1 ODN1–4) into oocytes to establish which ODNs are the most successful in downregulating
tpt1mRNA. As a negative control, an ODN was used against gfp (ODN GFP). After 24 hr, the level of tpt1mRNA was established. Injection of 10 ng
Tpt1 ODN3 resulted in the most significant decrease of tpt1 mRNA, down to 9% in comparison to the tpt1-mRNA level of uninjected oocytes
(100%). Error bars indicate the SEM.
(E) We injected 10 ng of different ODNs (anti-RAR ODN1–3) and the negative ODN GFP into oocytes to establish which ODNs downregulate RAR
mRNA most successfully. After 24 hr, the level of RAR mRNA was most downregulated by RAR ODN3, down to 12% in comparison to the RAR
mRNA level in control oocytes (100%). Error bars indicate the SEM.
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sequently, oct4 expression (Figure 3E). This result con-
firms that the downregulation of tpt1 mRNA is specific.
To determine more precisely how the level of tpt1
influences oct4 transcription, we injected different con-
centrations of mouse tpt1mRNA into oocyte cytoplasm.
An incubation period of 16 hr allowed for the mRNA to be
translated, and HeLa nuclei were then injected into the
oocyte germinal vesicle. After 8 hr of incubation, the
oct4 signal was already enhanced in comparison to con-
trol oocytes (Figure 3F). As a result, mouse tpt1 mRNA
injected into Xenopus oocytes was effective at enhanc-
ing oct4 transcription. These observations were inde-
pendent of the mRNA concentrations used (Figure 3E).
Hence, in our nuclear-transfer experiments, tpt1 over-
expression enhanced oct4. This suggests that Tpt1
might have an important role in regulating oct4; namely,
it might ensure a level required for pluripotency and nor-
mal development.
We were interested in whether Tpt1 is a transcription
factor specific for oct4 or whether it is a more generally
important component that might act on other pluripo-
tency genes. Using the same up- and down-regulation
procedure just described for oct4, we have tested the
transcriptional activation of the human pluripotency
gene nanog by using nuclear transfer to oocytes (Fig-
ure 3G) [27, 28]. nanog seems to be an important pluri-
potency gene because its overexpression increases
the efficiency of nuclear reprogramming by 200-fold in
cell-fusion experiments [29]. Overall, we found that a
reduction in the RAR did not significantly affect nanog
expression. However, we had expected some effect on
nanog expression because retinoic acid is known to
downregulate pluripotency genes [13, 18]. One explana-
tion for our finding is that Nanog or Nanog orthologs do
not exist in amphibians (NCBI blast). As a result, some
aspects of transcriptional activation upon nuclear trans-
fer might not be conserved between mammals and
amphibians. However, we saw a reduction in nanog
transcription after downregulation of tpt1 in oocytes
(Figure 3G). To test for binding of Tpt1 to nanog, we car-
ried out ChiP analysis in mouse ES cells and found that
Tpt1 bound to oct4, but not significantly to the immedi-
ate promoter of nanog (Figure 3B). This suggests that
Tpt1 regulates oct4 by binding to its DNA directly,
whereas Tpt1 might regulate nanog in an indirect way
or by binding to a distant site.
Overall, Tpt1 seems to represent a global regulator of
pluripotency. We suggest that Tpt1 might have a some-
what general role in establishing an embryonic pattern
of gene expression because it controls transcription of
oct4 and nanog. In support of this view, we have also
found that the transfection of tpt1 antisense RNA intomouse ES cells can reduce the transcription from the
oct4 promoter (Figures 4A–4C), suggesting a conserved
mechanism between mammals and amphibians.
The molecular events occurring after nuclear transfer
and the initiation of pluripotency are not well under-
stood. We describe here the first protein that has been
discovered to be required for activating transcription
of pluriptoency genes such as oct4 and nanog after nu-
clear transfer into oocytes. In the future, this type of
work might provide a generally applicable experimental
design, which in combination with the advantages of
Xenopus oocytes, might lead to the identification of
other proteins that activate pluripotency genes and
thereby further elucidate mechanisms involved in
nuclear reprogramming.
Experimental Procedures
Oligo Preparation for Gel Shifts
Complementary single-stranded 30 bp oligos that represent DNA
fragments of the oct4 promoter [30] were annealed to double-
stranded (DS) DNA. Longer DS oligo fragments were made with
PCR amplification. Oligos were end labeled with g-P32 ATP.
Gel Shifts
The phosphate binding buffer consisted of 20 mM phosphate
(pH 7.4), 10% glycerol, 3 mM MgCl2, 17 mM KCl, 2.5 mM DTT, and
50 mM–2 M NaCl. We used 8 ml oocyte extract per sample and pre-
pared it by mixing freshly obtained oocytes in presence of protease
inhibitors. Centrifuging the mixture overnight eliminated debris and
lipids. For the gel shift, 8 ml oocyte extract, 2 mg BSA, and 10 ml phos-
phate binding buffer were mixed with approximately 0.1 pmol radio-
actively labeled oligos and run on a native gel. To confirm binding of
Tpt1 to any one oligo, we added 1 ml of Tpt1 antibody (monoclonal
antibody anti-HRF/TCTP, Medical & Biological Laboratories) to the
sample before was running it on a gel.
Protein Recovery and Identification
Proteins were recovered directly from the gels. The samples
were washed, concentrated, and analyzed with MALDI-TOF mass
spectrometry.
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cells containing an additional integrated oct4 promoter driving an
egfp reporter were transfected with siRNA against tpt1. Upregula-
tion of egfp mRNA indicates that the targeted mRNA is required
for oct4 repression. Conversely, egfp-mRNA downregulation shows
that the mRNA is responsible for oct4 activation or maintenance.
(B) DNA primers and siRNA target sequences for knockdown are
shown. DNA primers were designed to detect reduction of the
mRNA of choice. The mouse housekeeping gene b-2-microglobulin
was used as a control and reference. siRNAs were designed to tar-
get specifically gfp, b-galactosidase, and tpt1. siRNA against tpt1
mRNA resulted in decrease down to 17% of its endogenous level
(not shown).
(C) FACS analysis of the siRNA experiments shows that Tpt1 siRNA
causes a decrease in oct4 transcription in mouse ES cells. Mouse ES
cells were transfected with siRNAs against b-galactosidase, gfp,
and tpt1, and the GFP level was monitored by FACS analysis after
48 hr, as expected. siRNA targeting b-galactosidase, which is usu-
ally not present in mouse ES cells, did not reduce the GFP level (neg-
ative control). siRNA against gfp resulted in a decrease of GFP,
showing that siRNA can downregulate a message and that this
can be detected by FACS analysis. siRNA targeting tpt1 gave rise
to a decrease in the GFP level, indicating that tpt1 is also an activator
of oct4 transcription in mouse ES cells. The corresponding downre-
gulation of the endogenous oct4 mRNA itself was also confirmed by
RT-PCR (data not shown). No differentiation was seen, because the
siRNA transfection was transient. The effect of the decrease was re-
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